ADMA Biologics Inc trades as part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Adam S. Grossman. ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.

Previous Intraday Performance:

The ADMA shares had a previous change of -2.13% which opened at 4.73 and closed at 4.60. It moved to an intraday high of 4.73 and a low of 4.37.

SeekingAlpha:  Daily Insider Ratings Round Up 5/23/19

Historical Performance:

Over the last five trading days, ADMA shares returned 10.05% and in the past 30 trading days it returned -6.69%. Over three months, it changed 15.00%. In one year it has changed -11.20% and within that year its 52 week high was 6.96 and its 52 week low was 2.08. ADMA stock is 121.15% above its 52 week low.

Our calculations result in a 200 day moving average of 4.72 and a 50 day moving average of 4.50. Right now, ADMA stock is trading -2.62% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.

SeekingAlpha:  Daily Insider Ratings Round Up 5/23/19


The company has a market cap of $272.9m with 59.3m shares outstanding and a float of 59.1m shares. Trading volume was 1,242,065 shares and has experienced an average volume of 989,577 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for ADMA Biologics Inc was -1.46 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.29.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019 -0.28
4thQtr 2018 -0.39
3rdQtr 2018 -0.33
2ndQtr 2018 -0.35
1stQtr 2018 -0.39

EPS growth is an important number as it indicates the future prospects of ADMA Biologics Inc; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -51.20% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 0.50% of insider ownership and 62.30% of institutional ownership.

The beta was calculated to be 2.95.

SeekingAlpha:  Advanced Emissions Solutions Inc. (ADES) CEO Heath Sampson on Q1 2019 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -368.91%, return on assets is -72.07%, price-to-sales is 16.89 and price-to-book is 27.18.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here